Biotech Values

[biomaven0]

>NVO

Maybe I haven't focused enough on FOB's for their insulin products. In this environment having marginally better new products probably isn't enough to protect them. I expect Victoza to do very well, but maybe that's not enough to compensate.

But if not NVO, then what's the buy-and-forget diabetes play?

Peter